Hypothalamic obesity is a complex condition that doesn’t always respond to traditional weight loss methods. Medications, hormonal therapy, and surgery may be necessary to see results. Hypothalamic ...
Rhythm Pharmaceuticals announced significant data regarding their treatments for acquired hypothalamic obesity during the Endocrine Society’s Annual Meeting. Presentations highlighted the promising ...
The last time I spoke about Rhythm Pharmaceuticals, Inc. (RYTM) it was in a Seeking Alpha article entitled "Rhythm: Late-Stage Study Win Brings About Change For Rare Obesity Disorder." With respect to ...
Rhythm Pharmaceuticals, Inc.'s IMCIVREE and new oral MC4R agonist, bivamelagon, show strong efficacy in rare obesity disorders, especially hypothalamic obesity (HO). HO represents a blockbuster market ...
Stocktwits on MSN
RYTM stock jumps 4% on Imcivree revenue growth: Firm awaits approval in acquired hypothalamic obesity by March
Imcivree is Rhythm’s only approved drug and the company is now looking forward to an FDA approval for the drug in the treatment of acquired hypothalamic obesity. ・The FDA is expected to rule on the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results